Saturday 17 October 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.03
0.53
−2.71%
Follow VRDN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
24.93 | 37.25 | 28.19 | 27.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.86) | (111.10) | (16.71) | (18.82) | |
P/B ratio |
5.62 | 4.47 | 3.97 | 3.51 | |
Price to Tangible BV |
5.62 | 4.47 | 3.97 | 3.58 | |
EV/Sales |
18.41 | 25.73 | 18.27 | 17.59 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.00) | (6.59) | (4.27) | (3.75) | |
EV/FCF |
(3.99) | (6.58) | (4.27) | (3.73) | |
Quick Ratio |
9.68 | 12.37 | 14.71 | 16.56 | |
Current Ratio |
11.28 | 12.65 | 15.15 | 16.95 | |
Net Debt/EBITDA |
11.45 | 6.63 | 6.04 | 5.79 | |
Debt/Assets |
3.62% | 5.55% | 6.39% | 22.07% | |
Debt/Equity |
0.04 | 0.07 | 0.08 | 0.37 | |
Asset Turnover |
0.10 | 0.09 | 0.10 | 0.08 | |
Operating CF/Net income |
2.45 | 0.20 | 1.14 | 0.83 | |
Capex/Depreciation |
0.12 | 0.15 | 0.01 | 0.98 | |
Interest Coverage |
(71.45) | (36.93) | (33.56) | (15.20) | |
Research and Development Expense of Revenue |
122.23% | 67,581.06% | 55,057.45% | 25,203.17% | |
Selling, General and Administrative Expense of Revenue |
34.47% | 25,510.61% | 27,431.91% | 19,357.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
15.94% | 9,082.58% | 9,496.45% | 5,980.28% | |
Graham Net Nets |
0.28 | 0.27 | 0.32 | 0.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.92%) | (10.57%) | (16.97%) | (18.35%) | |
Free Cash Flow Yield |
(18.49%) | (10.49%) | (15.20%) | (16.91%) | |
Revenue per Share |
0.86 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (0.28) | (1.17) | (0.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.04) | (0.28) | (1.17) | (0.99) | |
Cash per Share |
6.00 | 10.31 | 7.46 | 9.10 | |
Shareholders Equity per Share |
6.15 | 8.52 | 6.22 | 6.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.15 | 8.52 | 6.22 | 6.14 | |
Free Cash Flow |
(84.74) | (23.99) | (119.68) | (106.63) | |
Working Capital |
521.22 | 823.54 | 732.94 | 1,017.48 | |
Capital Expenditures |
(0.13) | (0.24) | (0.02) | (1.31) | |
Net Current Asset Value |
497.75 | 716.98 | 631.74 | 646.13 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 1.82 | 0.16 | 4.60 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 37.55 | |
Average Payables |
8.20 | 5.41 | 8.60 | 8.59 | |
Average Assets |
674.52 | 820.91 | 725.00 | 839.78 | |
Average Common Equity |
416.35 | 536.43 | 459.77 | 445.18 |
Columns are period end dates